Legacy Capital Wealth Partners LLC Sells 249 Shares of Johnson & Johnson $JNJ

Legacy Capital Wealth Partners LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 5,671 shares of the company’s stock after selling 249 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in Johnson & Johnson were worth $866,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. GFG Capital LLC bought a new stake in Johnson & Johnson in the second quarter valued at approximately $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the 1st quarter valued at about $52,000. Finally, Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Johnson & Johnson by 66.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after buying an additional 150 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.3%

JNJ opened at $206.89 on Friday. The company has a market cap of $498.46 billion, a P/E ratio of 19.97, a PEG ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company’s 50 day moving average is $191.33 and its 200-day moving average is $173.36. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $207.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. The Goldman Sachs Group upped their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a research report on Monday, October 20th. UBS Group raised their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Finally, Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.